Notis McConarty Edward Sells 240 Shares of Amgen, Inc. (NASDAQ:AMGN)

Notis McConarty Edward lessened its holdings in shares of Amgen, Inc. (NASDAQ:AMGN) by 2.0% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 11,717 shares of the medical research company’s stock after selling 240 shares during the quarter. Notis McConarty Edward’s holdings in Amgen were worth $2,160,000 as of its most recent SEC filing.

A number of other hedge funds have also made changes to their positions in the business. Manning & Napier Group LLC grew its stake in shares of Amgen by 7.5% in the 2nd quarter. Manning & Napier Group LLC now owns 182,508 shares of the medical research company’s stock worth $33,632,000 after acquiring an additional 12,735 shares in the last quarter. Hyman Charles D grew its stake in shares of Amgen by 6.1% in the 2nd quarter. Hyman Charles D now owns 3,711 shares of the medical research company’s stock worth $684,000 after acquiring an additional 215 shares in the last quarter. Logan Capital Management Inc. grew its stake in shares of Amgen by 14.7% in the 2nd quarter. Logan Capital Management Inc. now owns 68,784 shares of the medical research company’s stock worth $12,675,000 after acquiring an additional 8,794 shares in the last quarter. Wolff Financial Management LLC bought a new stake in shares of Amgen in the 2nd quarter worth $214,000. Finally, Westside Investment Management Inc. bought a new stake in shares of Amgen in the 2nd quarter worth $97,382,000. Institutional investors and hedge funds own 77.43% of the company’s stock.

NASDAQ AMGN traded down $4.78 during trading on Monday, hitting $182.44. 1,531,958 shares of the company’s stock traded hands, compared to its average volume of 2,814,827. The stock has a market capitalization of $112.28 billion, a PE ratio of 12.67, a price-to-earnings-growth ratio of 2.23 and a beta of 1.19. Amgen, Inc. has a 12-month low of $166.30 and a 12-month high of $210.19. The company has a quick ratio of 2.53, a current ratio of 2.89 and a debt-to-equity ratio of 2.58. The business’s 50 day simple moving average is $180.90.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings results on Tuesday, July 30th. The medical research company reported $3.97 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.58 by $0.39. Amgen had a net margin of 33.78% and a return on equity of 76.17%. The firm had revenue of $5.87 billion for the quarter, compared to the consensus estimate of $5.67 billion. During the same period in the prior year, the firm posted $3.83 earnings per share. The company’s revenue for the quarter was down 3.1% on a year-over-year basis. On average, research analysts expect that Amgen, Inc. will post 14.23 earnings per share for the current fiscal year.

The business also recently disclosed a quarterly dividend, which will be paid on Friday, September 6th. Investors of record on Thursday, August 15th will be given a $1.45 dividend. This represents a $5.80 annualized dividend and a dividend yield of 3.18%. Amgen’s dividend payout ratio (DPR) is 40.28%.

A number of equities analysts recently weighed in on the stock. Zacks Investment Research downgraded shares of Amgen from a “buy” rating to a “hold” rating in a report on Monday, April 15th. Mizuho reissued a “buy” rating and issued a $208.00 price target on shares of Amgen in a report on Monday, July 1st. JPMorgan Chase & Co. reissued a “hold” rating and issued a $190.00 price target on shares of Amgen in a report on Wednesday, May 15th. BMO Capital Markets set a $230.00 price target on shares of Amgen and gave the stock a “buy” rating in a report on Wednesday, July 31st. Finally, Oppenheimer set a $210.00 price target on shares of Amgen and gave the stock a “buy” rating in a report on Friday, May 24th. Eight research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus price target of $210.41.

In related news, Director Ronald D. Sugar sold 2,000 shares of the company’s stock in a transaction that occurred on Wednesday, July 3rd. The shares were sold at an average price of $187.58, for a total value of $375,160.00. Following the transaction, the director now directly owns 16,336 shares in the company, valued at $3,064,306.88. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 0.25% of the stock is currently owned by corporate insiders.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, and neuroscience. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, a pegylated protein to treat cancer patients; Prolia to treat postmenopausal women with osteoporosis; Aranesp to treat anemia; Xgeva for skeletal-related events prevention; Sensipar/Mimpara products to treat sHPT in chronic kidney disease; and EPOGEN to treat a lower-than-normal number of red blood cells.

Featured Story: Arbitrage

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.